Figure 5From: Cetuximab and radiation for primary and recurrent squamous cell carcinoma of the head and neck (SCCHN) in the elderly and multi-morbid patient: a single-centre experienceLocoregional PFS. 0: RIT as primary therapy; mean 31.5 months, 95% CI 24.4 - 38.6 months. 1: RIT for disease relapse; mean 8.0 months; 95% CI 5.4 - 10.7 months. 2: RIT as re-RT; mean 12.8 months; 95% CI 7.6 - 17.9 months. p = 0.009 (0 vs. 1); p = 0.001 (0 vs 2); p = ns (1 vs 2)Back to article page